Genotype-specific increase in plasma concentrations of activated coagulation factor VII in response to experimental inflammation

Summary

There is evidence that infection and inflammation might trigger an acute coronary event, but the mechanisms are unclear. Activated factor VII (FVIIa) is a potent coagulant that is under genetic control and a potential determinant of the outcome of acute myocardial infarction. This study investigated the acute FVIIa response to experimental inflammation. Forty healthy men and women were vaccinated with 1 ml of Salmonella Typhii vaccine. Plasma levels of FVIIa, FVII antigen (FVIIag), tissue factor (TF) activity and thrombin-antithrombin complex (TAT) were measured at baseline and up to 24 hours after inoculation. All subjects were genotyped for the FVII gene Arg353Gln polymorphism. Plasma concentrations of FVIIa, but not FVIIag, increased significantly with a peak at 10 hrs after vaccination. At 24 hrs FVIIa levels had returned to baseline. The FVIIa response to vaccination was significantly greater in subjects with the ArgArg genotype compared with ArgGln subjects.TAT increased, butTF activity was unchanged after vaccination. The results are of interest from a mechanistic viewpoint, since one explanation for the link between infection and acute myocardial infarction might be activation of coagulation. However, there is a need for further studies of the role of infection and inflammation in haemostasis.

Keywords

Gene regulation - inflammatory mediators - tissue factor/factorVII

• References

• 1 Fuster V, Badimon L, Badimon JJ. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
• 2 Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
• 3 Meade TW, Mellows S, Brozovic M. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 4 Heinrich J, Balleisen L, Schulte H. et al. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in health men. Arterioscler Thromb 1994; 14: 54-9.
• 5 Salomaa V, Rasi V, Pekkanen J. et al. Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J 1994; 15: 1293-9.
• 6 Folsom AR, Wu KK, Rosamund WD. et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 1102-8.
• 7 Lowe GD, Rumley A, McMahon AD. et al. Interleukin- 6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.
• 8 Benamer H, de Prost D, Bridey F. et al. Gender difference in factor VII and in activated factor VII levels in unstable angina. Thromb Haemost 1996; 75: 981.
• 9 Hoffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1992; 12: 267-70.
• 10 Moor E, Silveira A, van’t Hooft F. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
• 11 Balleisen L, Bailey J, Epping PH. et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-9.
• 12 Folsom AR, Wu KK, Davis CE. et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 13 Green F, Kelleher C, Wilkes H. et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
• 14 Bernardi F, Arcieri P, Bertina RM. et al. Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol 1997; 17: 2548-53.
• 15 Bernardi F, Marchetti G, Pinotti M. et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.
• 16 Hunault M, Arbini AA, Lopaciuk S. et al. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
• 17 Girelli D, Russo C, Ferraresi P. et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-80.
• 18 Iacoviello L, Di Castelnuovo A, DeKnijff P. et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
• 19 Lane A, Green F, Scarabin PY. et al. Factor VII Arg/ Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
• 20 Doggen CJ, MangerCats V. et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
• 21 Batalla A, Alvarez R, Reguero JR. et al. Lack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men,. Int J Cardiol 2001; 80: 209-21
• 22 Becker AE, de Boer OJ, vanDerWal AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med 2001; 52: 289-97.
• 23 Smeeth L, Thomas SL, Hall AJ. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-8.
• 24 Romano M, Guagnano MT, Pacini G. et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 2003; 88: 5321-6.
• 25 Sorensen BB, Hedner U, Erhardtsen F. rFVIIai in acute coronary syndromes. Semin Vasc Med 2003; 3: 199-204.
• 26 Hingorani AD, Cross J, Kharbanda RK. et al. Acute systematic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-9.
• 27 Lagercrantz J, Bergman M, Lundman P. et al. No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein IIIa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction. Blood Coagul Fibrinolysis 2003; 14: 749-53.
• 28 Bennermo M, Held C, Stemme S. et al. Genetic predisposition of the Interleukin-6 response to inflammation: implications for a variety of major diseases?. Clin Chem 2004; 50: 2136-40.
• 29 Morrisey JH, Macik BG, Neuenschwander PF. et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
• 30 Mrozikiewicz PM, Cascorbi I, Ziemer S. et al. Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol 2000; 36: 1520-5.
• 31 Kjalke M, Silveira A, Hamsten A. et al. Plasma lipoproteins enhance tissue-factor-independent factor VII activation. Arterioscler Thromb Vasc Biol 2000; 20: 1835-41.
• 32 Lindman AS, Pedersen JI, Arnesen H. et al. Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease. Thromb Res 2004; 113: 157-65.
• 33 Silveira A, Karpe F, Johnsson H. et al. In vivo demonstration in humans that large postprandial triacylglycerol- rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996; 16: 1333-9.
• 34 Miller GJ, Martin JC, Mitropoulos KA. et al. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood 1996; 87: 4187-96.
• 35 Khovidhunkit W, Kim MS, Memon RA. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-96.
• 36 Uchiumi D, Kobayashi M, Tachikawa T. et al. Subcutaneous and continuous administration of lipopolysaccharide increases serum levels of triglyceride and monocyte chemoattractant protein-1 in rats. J Periodontal Res 2004; 39: 120-8.
• 37 Eriksson-Berg M, Silveira A, Orth-Gomer K. et al. Coagulation factor VII in middle-aged women with and without coronary heart disease. Thromb Haemost 2001; 85: 787-92.
• 38 Pinotti M, Bertolucci C, Portaluppi F. et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005; 25: 646-9.